Multivariate-adjusted linear regression analyses of albumin-creatinine ratio and angiopoietin-2^a.

<p>Note:</p>a<p>Albuminuria (ACR) was natural logarithm transformed.</p>b<p>Model 1: Ang-2+age+gender.</p>c<p>Model 2: Model 1+traditional risk (hypertension, diabetes, dyslipidemia, mean brachial SBP, eGFR) +nontraditional risk (Calcium phosphate product, hemoglobin, high sensitive C reactive protein, medication including ACE inhibitor, ARB, statin, calcium channel blocker, β-blocker, pentoxifylline).</p>d<p>Model 3: stepwise regression method for variables in model 2.</p><p>Abbreviations: ACR, urine albumin-creatinine ratio; SBP, systolic blood pressure; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.</p

Plasma levels of angiotrophic growth factors.

<p><i>Note</i>: Data expressed as median (interquartile range).</p>*<p><i>P</i><0.05 compared with normoalbuminuria group (Chi-Square test in categorical variables, Mann-Whitney U test in continuous variables).</p>**<p><i>P</i><0.0001 compared with normoalbuminuria group (Chi-Square test in categorical variables, Mann-Whitney U test in continuous variables).</p><p><i>Abbreviations</i>: Ang-1, angiopoietin-1; Ang-2, angiopoietin-2; VEGF, vascular endothelial growth factor; sTie-2, soluble Tie-2 receptor.</p

Plasma angiopoietin-2 was correlated with malnutrition, inflammation, and albuminuria.

<p>Univariate regression analysis showed the linear correlation of plasma angiopoietin-2 (Ang-2) with urine albumin-creatinine ratio (ACR) (A), high sensitive C-reactive protein (hsCRP) (B), and serum albumin (C). The levels of plasma Ang-2, ACR and hsCRP were expressed as natural logarithm (ln); <i>r</i>, Pearson correlation coefficient.</p

Clinical characteristics of the patients^a.

<p>Note:</p>a<p>Continuous and categorical variables were expressed as median (interquartile range) and percentage (number) respectively.</p>b<p>Patients were stratified based on albuminuria (urine albumin-creatinine ratio) as normoalbuminuria (<30 mg/g), microalbuminuria (30–300 mg/g), macroalbuminuria (>300 mg/g).</p>c<p>Chi-Square test in categorical variables, Kruskall-Wallis test in continuous variables.</p>*<p>P<0.05 compared with normoalbuminuria group (Chi-Square test in categorical variables, Mann-Whitney U test in continuous variables).</p>**<p>P<0.0001 compared with normoalbuminuria group (Chi-Square test in categorical variables, Mann-Whitney U test in continuous variables).</p><p>Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; Calcium phosphate product, Calcium x Phosphate x 4; hsCRP, high sensitivity C-reactive protein; iPTH, intact parathyroid hormone.</p

Konstrukční návrh akčního subsystému servisního robotu

Import 20/04/2006Prezenční výpůjčkaVŠB - Technická univerzita Ostrava. Fakulta strojní. Katedra (354) robototechnik

Multivariate analyses of the risk factors for patient and technique survival using Cox's models with repeatedly measured time-dependent covariates.

<p>NOTES. Conversion factors for units: HDL in mg/dL to mmol/L, ×0.02586; urea nitrogen in mg/dL to mmol/L, ×0.357; creatinine in mg/dL to µmol/L, ×88.4.</p><p>Abbreviations: HDL, high-density lipoprotein cholesterol.</p>1<p>Cox's model with 4 repeatedly measured time-dependent covariates (glucose concentration, weekly renal Kt/V, blood urea nitrogen, and creatinine), adjusted generalized <i>R</i>² = 0.58.</p>2<p>Cox's model with 7 repeatedly measured time-dependent covariates (diabetes mellitus, glucose concentration, glucose weight, icodextrin solution, weekly renal Kt/V, weekly peritoneal Kt/V, and HDL), adjusted generalized <i>R</i>² = 0.31.</p><p>*Each subject's dialysate prescription was represented by (1) the accumulative glucose exposure and (2) the accumulative volumes of icodextrin solution, from the time of PD initiation to each time at which a PD technique failure or death occurred in the Cox's models for PD technique failure or mortality.</p

Frequency distribution of average dialysate glucose concentration in the study population.

<p>Average dialysate glucose concentration of each subject was calculated as: [total glucose weight]/[total volume of glucose solution] administered since initiation of PD.</p

Summary of patient selection.

<p>ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.</p

Baseline characteristics of study participants.

<p>Baseline characteristics of study participants.</p

Hazard ratios (95% confidence interval)^* for study outcomes comparing ACEI therapy with ARB therapy, by subgroups of different age, Charlson comorbidity index score, or year of index date.

<p>Hazard ratios (95% confidence interval)^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177654#t005fn001" target="_blank">*</a>} for study outcomes comparing ACEI therapy with ARB therapy, by subgroups of different age, Charlson comorbidity index score, or year of index date.</p